This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (43)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Potential for Oral-Ophthalmic Drug Interaction

Tim I. Edeki, MD, PhD; Huabing He, PharmD; Alastair J. J. Wood, MD

JAMA. 1995;274(20):1611-1613.

Abstract
Objective.
—To determine whether the effects of topically administered timolol in an individual would be dependent on the presence or absence in that individual of the P-450 enzyme CYP2D6 and whether the effects of topically administered timolol would be increased and its metabolism decreased by the oral administration of quinidine, a known inhibitor of CYP2D6.

Design.
—Single-blind randomized crossover comparison of topical timolol, placebo, and the effects of inhibition of timolol metabolism by oral quinidine.

Setting.
—Clinical research center of an academic medical center.

Participants.
—Eight male extensive metabolizers (EMs) and five male poor metabolizers (PMs) of debrisoquin.

Intervention.
—Two drops of 0.5% timolol or artificial tears were administered into each nostril in random order, and placebo or 50 mg of quinidine was administered orally to the EMs in random order, followed 30 minutes later by either the timolol or placebo drops.

Main Outcome Measurement.
—Plasma timolol concentrations were measured by high-pressure liquid chromatography, while the extent of β-blockade was determined by the suppression of exercise-induced rise in heart rate.

Results.
—The exercise heart rate was reduced following timolol eye drops compared with placebo in both EMs (P<.001) and PMs (P<.001) with significantly greater heart rate reduction (P=.01) higher plasma timolol concentration in PMs compared with EMs (P=.03). Administration of quinidine with timolol eye drops to EMs resulted in a further significant reduction in heart rate (P=.02) and increase in plasma timolol concentration (P=.04).

Conclusions.
—An individual's debrisoquin phenotype is an important determinant of β-blockade following timolol eye drops, and metabolism of timolol is inhibited and β-blockade increased by coadministration of oral quinidine. Clinicians should be aware of the potential for drug interactions that occur when orally administered drugs inhibit the metabolism of a topically administered drug.

(JAMA. 1995;274:1611-1613)

Author Affiliations
From the Clinical Pharmacology Program, Department of Pharmacology, Meharry Medical College (Dr Edeki), and Division of Clinical Pharmacology, Vanderbilt University School of Medicine (Drs He and Wood), Nashville, Tenn,

Footnotes
Presented in part at the annual meetings of the American Federation for Clinical Research, Baltimore, Md, May 1, 1992, and the American Society for Clinical Pharmacology and Therapeutics, Honolulu, Hawaii, March 24, 1993.

Reprint requests to Division of Clinical Pharmacology, Vanderbilt University School of Medicine, 546 Medical Research Bldg, Nashville, TN 37232 (Dr Wood).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intraocular Pressure Response to Topical {beta}-Blockers Associated With an ADRB2 Single-Nucleotide Polymorphism
McCarty et al.
Arch Ophthalmol 2008;126:959-963.
ABSTRACT | FULL TEXT  

PhRMA White Paper on ADME Pharmacogenomics
Williams et al.
J Clin Pharmacol 2008;48:849-889.
ABSTRACT | FULL TEXT  

Timolol Metabolism in Human Liver Microsomes Is Mediated Principally by CYP2D6
Volotinen et al.
Drug Metab. Dispos. 2007;35:1135-1141.
ABSTRACT | FULL TEXT  

Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner and Begg
Pharmacol. Rev. 2006;58:521-590.
ABSTRACT | FULL TEXT  

Implications of Cytochrome P450 Interactions When Prescribing Medication for Hypertension
Flockhart and Tanus-Santos
Arch Intern Med 2002;162:405-412.
ABSTRACT | FULL TEXT  

Medical Management of Glaucoma
Alward
NEJM 1998;339:1298-1307.
FULL TEXT  

Initial Treatment for Open-Angle Glaucoma--Medical, Laser, or Surgical?: Laser Trabeculoplasty Is the Treatment of Choice for Chronic Open-Angle Glaucoma
Jampel
Arch Ophthalmol 1998;116:240-241.
FULL TEXT  

Topical {beta}-Adrenergic Antagonists and Quinidine: A Risky Interaction
Higginbotham
Arch Ophthalmol 1996;114:745-746.
ABSTRACT  

Excessive {beta}-Blockade With Timolol Eye Drops
Kalenak
JAMA 1996;275:985-985.
ABSTRACT  

Excessive {beta}-Blockade With Timolol Eye Drops
Novack
JAMA 1996;275:985-985.
ABSTRACT